Sanofi (FR)

Alle Meldungen

25.06

Sanofi (FR) Sanofi (FR)

Press Release: Availability of the Q2 2024 Aide-mémoire

Paris, France – June 25, 2024 . Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q2-results-2024 As for...

Zur Pressemeldung auf www.sanofi.com
25.06

Sanofi (FR) Sanofi (FR)

Media Update: Riliprubart one-year results from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy

First phase 2 study to evaluate three separate participant cohorts, including those who had failed or had an inadequate response to standard-of-care (SOC) treatment and those who had never received treatment Riliprubart showed efficacy and safety...

Zur Pressemeldung auf www.sanofi.com
21.06

Sanofi (FR) Sanofi (FR)

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

In her new role, Audrey will be responsible for Sanofi’s stakeholder engagement globally, and oversee the company’s corporate social responsibility strategy, not-for-profit Global Health Unit and Sanofi’s philanthropic arm, Foundation S . Audrey...

Zur Pressemeldung auf www.sanofi.com
20.06

Sanofi (FR) Sanofi (FR)

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. This agreement is designed to enable...

Zur Pressemeldung auf www.sanofi.com
03.06

Sanofi (FR) Sanofi (FR)

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible...

Zur Pressemeldung auf www.sanofi.com
31.05

Sanofi (FR) Sanofi (FR)

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the...

Zur Pressemeldung auf www.sanofi.com
31.05

Sanofi (FR) Sanofi (FR)

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

Paris, May 31, 2024. Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10 th year, the program demonstrates the ongoing commitment of Sanofi and its Board of...

Zur Pressemeldung auf www.sanofi.com
31.05

Sanofi (FR) Sanofi (FR)

Media Update: Sanofi update on Zantac litigation

Paris, May 31, 2024 . Sanofi is disappointed with the State of Delaware court’s decision not to exclude plaintiffs’ experts from the cases and intends to appeal. There is no reliable scientific evidence that Zantac can cause cancer, just as was held...

Zur Pressemeldung auf www.sanofi.com
2023

Sanofi (FR) Sanofi (FR)

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related...

Zur Pressemeldung auf www.sanofi.com
2023

Sanofi (FR) Sanofi (FR)

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

Data presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhibitor, addresses disability accumulation that occurs independently from relapse activity Global regulatory submissions will begin in H2 2024 Paris, September 20,...

Zur Pressemeldung auf www.sanofi.com

Wem folgen?

Schultz Gruppe
Folgen
Rock Capital Group
Folgen
Volkstheater
Folgen

Mehr anzeigen

Trends

Black Friday
Folgen
Tesla
Folgen
Menschenrechte
Folgen
Advent
Folgen
Home Office
Folgen
Aktionstag
Folgen
Fachkräftemangel
Folgen

Mehr anzeigen

uncovr pure news - Die neue Art Presseinhalte zu recherchieren. Mehr Info